Molbio Diagnostics Limited Q1 FY27 results deck summary

Results deck of 8 Sep 2026, summarised by AI from the filing.

Total income ₹411.5 cr (Q1 FY26: ₹100.5 cr), EBITDA ₹103.7 cr (Q1 FY26: ₹(14.5) cr), PAT ₹52.7 cr (Q1 FY26: ₹(23.9) cr).

Key takeaways

1. Q1 FY27 results Total income ₹411.5 cr (Q1 FY26: ₹100.5 cr), EBITDA ₹103.7 cr (Q1 FY26: ₹(14.5) cr), PAT ₹52.7 cr (Q1 FY26: ₹(23.9) cr).
2. Guidance No forward guidance was provided in the presentation.
3. Growth driver Growth led by test-kit consumption across 12,500+ Truenat devices sold in 90+ countries.
4. Risk Business has a non-linear revenue profile with performance varying across quarters.

Original filing on BSE

Molbio Diagnostics Limited Q1 FY27 results

As filed: Revenue ₹399 cr, EBITDA ₹91.6 cr, PAT ₹56.6 cr, EBITDA margin 22.9%.

Not scored. No result for the same quarter last year.

Molbio Diagnostics Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (8 Sep 2026), Results deck (8 Sep 2026), Results press release (7 Sep 2026)